ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0719

A Combined Transcriptomics and Proteomics Approach to Identify Immune Signatures in ANCA-Associated Glomerulonephritis

Ivana Stojkic1, Arnon Arazi2, Huijuan Song3, Pearlly Yan3, Estela Puchulu-Campanella3, Hubao Wang3, Lynn Fussner3, Brad Rovin4, Stacy Ardoin1 and Salem Almaani3, 1Nationwide Children's Hospital, Columbus, OH, 2The Feinstein Institutes for Medical Research, Manhasset, 3OSU, Columbus, OH, 4The Ohio State University, Columbus, OH

Meeting: ACR Convergence 2025

Keywords: gender, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0711–0730) Vasculitis – ANCA-Associated Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: ANCA-associated vasculitis frequently involves the kidneys causing glomerulonephritis (AAGN). Despite advances in treatment, many patients develop end-stage kidney disease. An improved understanding of the immune drivers of AAGN has the potential to improve treatment outcomes. To achieve that goal, we utilized a combined transcriptomics/compartmental proteomics approach to identify the major immune pathways driving AAGN.

Methods: Formalin-fixed paraffin embedded kidney biopsies of 23 patients with AAGN and 5 healthy controls (pre-implantation kidney donor biopsy) were used. For transcriptomics, RNA was extracted and bulk RNAseq was performed on all 23 AAGN biopsies and controls. Differential expression analysis was performed using the DESeq framework. For proteomics, laser capture microdissection was utilized to collect the glomerular and tubulointerstitial compartments separately using 10 AAGN biopsies and all controls. Peptides were extracted and submitted for mass-spectrometric analysis. After normalization, differential expression analysis was done using T-tests. The Benjamini-Hochberg method was used for multiple hypothesis testing correction in all experiments. Differentially abundant mRNA and peptide spectral counts were used to identify enriched immune pathways using Ingenuity pathway analysis.

Results: Patient and disease characteristics of the full (transcriptomic) and proteomics cohort are described in table 1. The top enriched pathways in each of the 3 experiments (whole tissue transcriptomics, glomerular proteomics, tubulointerstitial proteomics) are depicted in Figure 1a-c. Comparison analysis using data from the 3 experiments demonstrated many shared enriched and upregulated pathways including complement, neutrophil degranulation, and FC gamma receptor signaling. PD-1/PDL1 and IL-10 signaling were downregulated across the 3 tissues studied. Upstream analysis demonstrated upregulation of TNF, INF-gamma, INF-alpha, and IL-6.

Conclusion: Analysis of biopsies from patients with AAGN demonstrated largely similar upregulated/downregulated immune pathways and upstream regulators when comparing transcriptomic and compartmental proteomics approaches. These may help inform patient stratification and therapy development.

Supporting image 1

Supporting image 2Top 20 upregulated pathways of immunologic relevance in a) transcriptomic data b) glomerular proteomic data and c) tubulointerstitial proteomic data

Supporting image 3Heatmap of identified canonical pathways and upstream regulators across transcriptomic and proteomic datasets


Disclosures: I. Stojkic: None; A. Arazi: None; H. Song: None; P. Yan: None; E. Puchulu-Campanella: None; H. Wang: None; L. Fussner: None; B. Rovin: Alexion, 2, Artiva, 2, 11, AstraZeneca, 2, Aurinia, 2, 5, Biogen, 2, 5, Bristol Myers Squibb, 2, Cabelleta, 2, Century, 2, F. Hoffman-La Roche Ltd/Genentech, Inc., 2, GlaxoSmithKlein(GSK), 2, Novartis, 2; S. Ardoin: None; S. Almaani: None.

To cite this abstract in AMA style:

Stojkic I, Arazi A, Song H, Yan P, Puchulu-Campanella E, Wang H, Fussner L, Rovin B, Ardoin S, Almaani S. A Combined Transcriptomics and Proteomics Approach to Identify Immune Signatures in ANCA-Associated Glomerulonephritis [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/a-combined-transcriptomics-and-proteomics-approach-to-identify-immune-signatures-in-anca-associated-glomerulonephritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-combined-transcriptomics-and-proteomics-approach-to-identify-immune-signatures-in-anca-associated-glomerulonephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology